Price: $137.7000
$-22.29 
-13.932%
|
| Day's High:
| $140.4600067138672
| Week Perf:
| -14.6 %
|
| Day's Low: |
$ 137.12 |
30 Day Perf: |
-11.92 % |
| Volume (M): |
10,243,052 |
52 Wk High: |
$ 170.46 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$145.34 |
| Open: |
$139.94 |
52 Wk Low: |
$121.57 |
|
|
| Market Capitalization (Millions $) |
269,203 |
| Shares
Outstanding (Millions) |
1,955 |
| Employees |
75,267 |
| Revenues (TTM) (Millions $) |
70,725 |
| Net Income (TTM) (Millions $) |
17,991 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
2,210 |
Business Description
Novartis AG is a Swiss multinational pharmaceutical company that specializes in developing and producing pharmaceutical products, generic drugs, vaccines, and medical devices. Novartis was formed in 1996 following the merger of two pharmaceutical companies e Ciba-Geigy and Sandoz. The company is headquartered in Basel, Switzerland, and operates in over 180 countries worldwide.
Novartis has a diversified product portfolio, which includes prescription drugs, over-the-counter (OTC) products, and animal health products. The company has a strong focus on research and development (R&D), with significant investments in clinical trials and new drug development. Novartis has over 65,000 employees globally, with roughly half of them working in research and development.
The company's operations are divided into three major business segments e Innovative Medicines, Sandoz, and Alcon. The Innovative Medicines business segment focuses on discovering, developing, and marketing innovative drugs for various therapeutic areas such as cardiovascular, neuroscience, immunology, and oncology. Sandoz is responsible for manufacturing and distributing generic drugs and biosimilars. Alcon, which was acquired by Novartis in 2011, produces eye care products such as contact lenses, eye drops, and surgical instruments.
Novartis has a strong global presence, with significant market share in Europe, Asia, and North America. The company reinvests a significant portion of its profits into R&D to maintain its position as a leading pharmaceutical company. Its commitment to R&D has resulted in several groundbreaking products, including cancer treatments, gene therapies, and cell-based therapies.
Novartis also has a strong sustainability and corporate social responsibility (CSR) strategy. The company is committed to reducing its environmental impact, improving access to healthcare, and supporting communities in need. It has established various partnerships with healthcare organizations, academic institutions, and government agencies to advance its CSR initiatives.
In conclusion, Novartis AG is a leading pharmaceutical company with a diversified product portfolio, a strong R&D focus, a global presence, and a commitment to sustainability and CSR. Its innovative medicines and products have improved the lives of millions of people worldwide.
Company Address: Lichtstrasse 35 Basel 4056
Company Phone Number: 324-1111 Stock Exchange / Ticker: NYSE NVS
|
|
| |
| Switzerland |
|
 2.46 % |
of total Revenue |
| US |
|
41.17 % |
of total Revenue |
| China |
|
7.39 % |
of total Revenue |
| Germany |
|
6.94 % |
of total Revenue |
| Other |
|
38.26 % |
of total Revenue |
| Change to prior year-end |
|
0 % |
of total Revenue |
| US Change to prior year-end |
|
0 % |
of total Revenue |
| Europe |
|
29.52 % |
of total Revenue |
| Europe Change to prior year-end |
|
0 % |
of total Revenue |
| Asia Africa Australasia |
|
19.05 % |
of total Revenue |
| Asia Africa Australasia Change to prior year-end |
|
0 % |
of total Revenue |
| Canada and Latin America |
|
6.48 % |
of total Revenue |
| Canada and Latin America Change to prior year-end |
|
0 % |
of total Revenue |
| Established Markets |
|
71.56 % |
of total Revenue |
| Established Markets Change to prior year-end |
|
0 % |
of total Revenue |
| Emerging Growth Markets |
|
24.66 % |
of total Revenue |
| Emerging Growth Markets Change to prior year-end |
|
0 % |
of total Revenue |
| Rest of the world |
|
55.05 % |
of total Revenue |
| Top 20 products |
|
78.54 % |
of total Revenue |
| Cardiovascular renal and metabolic |
|
15.81 % |
of total Revenue |
| Cardiovascular renal and metabolic Entresto |
|
13.67 % |
of total Revenue |
| Cardiovascular renal and metabolic Leqvio |
|
2.11 % |
of total Revenue |
| Cardiovascular renal and metabolic Vanrafia |
|
0.02 % |
of total Revenue |
| Cardiovascular renal and metabolic Top 20 products Entresto |
|
13.67 % |
of total Revenue |
| Cardiovascular renal and metabolic Top 20 products Leqvio |
|
2.11 % |
of total Revenue |
| Immunology |
|
18.16 % |
of total Revenue |
| Immunology Cosentyx |
|
11.77 % |
of total Revenue |
| Immunology Ilaris |
|
3.32 % |
of total Revenue |
| Immunology Xolair |
|
3.04 % |
of total Revenue |
| Immunology Rhapsido |
|
0.03 % |
of total Revenue |
| Immunology Top 20 products Cosentyx |
|
11.77 % |
of total Revenue |
| Immunology Top 20 products Ilaris |
|
3.32 % |
of total Revenue |
| Immunology Top 20 products Xolair |
|
3.04 % |
of total Revenue |
| Neuroscience |
|
10.57 % |
of total Revenue |
| Neuroscience Kesimpta |
|
7.81 % |
of total Revenue |
| Neuroscience Zolgensma |
|
2.17 % |
of total Revenue |
| Neuroscience Aimovig |
|
0.59 % |
of total Revenue |
| Neuroscience Top 20 products Kesimpta |
|
7.81 % |
of total Revenue |
| Neuroscience Top 20 products Zolgensma |
|
2.17 % |
of total Revenue |
| Oncology |
|
29.7 % |
of total Revenue |
| Oncology Kisqali |
|
8.44 % |
of total Revenue |
| Oncology Tafinlar Mekinist |
|
3.91 % |
of total Revenue |
| Oncology Jakavi |
|
3.72 % |
of total Revenue |
| Oncology Pluvicto |
|
3.52 % |
of total Revenue |
| Oncology Promacta Revolade |
|
2.89 % |
of total Revenue |
| Oncology Scemblix |
|
2.27 % |
of total Revenue |
| Oncology Tasigna |
|
1.95 % |
of total Revenue |
| Oncology Lutathera |
|
1.44 % |
of total Revenue |
| Oncology Fabhalta |
|
0.89 % |
of total Revenue |
| Oncology Piqray Vijoice |
|
0.67 % |
of total Revenue |
| Oncology Top 20 products Kisqali |
|
8.44 % |
of total Revenue |
| Oncology Top 20 products Tafinlar Mekinist |
|
3.91 % |
of total Revenue |
| Oncology Top 20 products Jakavi |
|
3.72 % |
of total Revenue |
| Oncology Top 20 products Pluvicto |
|
3.52 % |
of total Revenue |
| Oncology Top 20 products Promacta Revolade |
|
2.89 % |
of total Revenue |
| Oncology Top 20 products Scemblix |
|
2.27 % |
of total Revenue |
| Oncology Top 20 products Tasigna |
|
1.95 % |
of total Revenue |
| Oncology Top 20 products Lutathera |
|
1.44 % |
of total Revenue |
| Oncology Top 20 products Fabhalta |
|
0.89 % |
of total Revenue |
| Established Brands Sandostatin Group |
|
2.14 % |
of total Revenue |
| Established Brands Exforge Group |
|
1.28 % |
of total Revenue |
| Established Brands Lucentis |
|
1.13 % |
of total Revenue |
| Established Brands Diovan Group |
|
1.07 % |
of total Revenue |
| Established Brands Galvus Group |
|
0.86 % |
of total Revenue |
| Established Brands Kymriah |
|
0.67 % |
of total Revenue |
| Established Brands Contract manufacturing |
|
2.5 % |
of total Revenue |
| Established Brands Other |
|
12.32 % |
of total Revenue |
| Established Brands Top 20 products Sandostatin Group |
|
2.14 % |
of total Revenue |
| Established Brands Top 20 products Exforge Group |
|
1.28 % |
of total Revenue |
| Established Brands Top 20 products Lucentis |
|
1.13 % |
of total Revenue |
| Established Brands Top 20 products Diovan Group |
|
1.07 % |
of total Revenue |
| Established Brands Established Brands |
|
21.98 % |
of total Revenue |
| US Top 20 products |
|
37.33 % |
of total Revenue |
| US Cardiovascular renal and metabolic Top 20 products Entresto |
|
5.8 % |
of total Revenue |
| US Cardiovascular renal and metabolic Top 20 products Leqvio |
|
1.01 % |
of total Revenue |
| US Immunology Top 20 products Cosentyx |
|
6.77 % |
of total Revenue |
| US Immunology Top 20 products Ilaris |
|
1.84 % |
of total Revenue |
| US Neuroscience Top 20 products Kesimpta |
|
5.19 % |
of total Revenue |
| US Neuroscience Top 20 products Zolgensma |
|
0.73 % |
of total Revenue |
| US Oncology Top 20 products Kisqali |
|
5.25 % |
of total Revenue |
| US Oncology Top 20 products Tafinlar Mekinist |
|
1.53 % |
of total Revenue |
| US Oncology Top 20 products Pluvicto |
|
2.82 % |
of total Revenue |
| US Oncology Top 20 products Promacta Revolade |
|
1.12 % |
of total Revenue |
| US Oncology Top 20 products Scemblix |
|
1.45 % |
of total Revenue |
| US Oncology Top 20 products Tasigna |
|
0.86 % |
of total Revenue |
| US Oncology Top 20 products Lutathera |
|
1.04 % |
of total Revenue |
| US Oncology Top 20 products Fabhalta |
|
0.56 % |
of total Revenue |
| US Established Brands Top 20 products Sandostatin Group |
|
1.29 % |
of total Revenue |
| US Established Brands Top 20 products Exforge Group |
|
0.01 % |
of total Revenue |
| US Established Brands Top 20 products Diovan Group |
|
0.06 % |
of total Revenue |
| Rest of the world Top 20 products |
|
41.22 % |
of total Revenue |
| Rest of the world Cardiovascular renal and metabolic Top 20 products Entresto |
|
7.87 % |
of total Revenue |
| Rest of the world Cardiovascular renal and metabolic Top 20 products Leqvio |
|
1.1 % |
of total Revenue |
| Rest of the world Immunology Top 20 products Cosentyx |
|
4.99 % |
of total Revenue |
| Rest of the world Immunology Top 20 products Ilaris |
|
1.49 % |
of total Revenue |
| Rest of the world Immunology Top 20 products Xolair |
|
3.04 % |
of total Revenue |
| Rest of the world Neuroscience Top 20 products Kesimpta |
|
2.62 % |
of total Revenue |
| Rest of the world Neuroscience Top 20 products Zolgensma |
|
1.45 % |
of total Revenue |
| Rest of the world Oncology Top 20 products Kisqali |
|
3.19 % |
of total Revenue |
| Rest of the world Oncology Top 20 products Tafinlar Mekinist |
|
2.38 % |
of total Revenue |
| Rest of the world Oncology Top 20 products Jakavi |
|
3.72 % |
of total Revenue |
| Rest of the world Oncology Top 20 products Pluvicto |
|
0.7 % |
of total Revenue |
| Rest of the world Oncology Top 20 products Promacta Revolade |
|
1.76 % |
of total Revenue |
| Rest of the world Oncology Top 20 products Scemblix |
|
0.81 % |
of total Revenue |
| Rest of the world Oncology Top 20 products Tasigna |
|
1.09 % |
of total Revenue |
| Rest of the world Oncology Top 20 products Lutathera |
|
0.4 % |
of total Revenue |
| Rest of the world Oncology Top 20 products Fabhalta |
|
0.33 % |
of total Revenue |
| Rest of the world Established Brands Top 20 products Sandostatin Group |
|
0.85 % |
of total Revenue |
| Rest of the world Established Brands Top 20 products Exforge Group |
|
1.27 % |
of total Revenue |
| Rest of the world Established Brands Top 20 products Lucentis |
|
1.13 % |
of total Revenue |
| Rest of the world Established Brands Top 20 products Diovan Group |
|
1 % |
of total Revenue |
| Rest of portfolio |
|
17.68 % |
of total Revenue |
| US Rest of portfolio |
|
3.84 % |
of total Revenue |
| Rest of the world Rest of portfolio |
|
13.84 % |
of total Revenue |
1.23%